Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye drop could ease severe allergy in kids

NCT ID NCT07169695

Disease control Sponsor: Laboratoires Thea Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new eye drop called T1695 against an existing treatment (ciclosporin) for children aged 4 to 17 with moderate to severe vernal keratoconjunctivitis, a serious allergic eye condition. About 120 participants will use the drops for 4 weeks to see which better reduces corneal damage. The goal is to find a safer or more effective option for managing this chronic eye allergy.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
T1695 eye drops
What this could lead to
If T1695 works better than ciclosporin, it could offer a new treatment option for children with severe eye allergies.
What could go wrong
This is an early Phase 2 trial with only 120 participants, so results may not confirm effectiveness. The condition can be serious, but the new drug may not prove superior or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2026

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

4 to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main Inclusion Criteria: * Informed consent signed and dated * Male or female participant from 4 years to less than 18 years old. * Participant with grading score of 3 or 4 on the Bonini scale for clinical grading of VKC in each eye. Main Exclusion Criteria: Participants must not have any conditions which might exclude them from participating, could interfere with the study, or pose an unacceptable risk to their health.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Moderate to severe vernal keratoconjunctivitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Conjunctivitis, Allergic vernal keratoconjunctivitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Moderate to severe vernal keratoconjunctivitis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Agrawal Hospital

    RECRUITING

    Jaipur, India

  • Disha Eye Hospitals - Barrackpore

    RECRUITING

    Kolkata, West Bengal, India

  • L V Prasad Eye Institute

    RECRUITING

    Visakhapatnam, India

  • L. V. Prasad Eye Institute (LVPEI)

    RECRUITING

    Hyderabad, India

  • M&J Institute of Ophthalmology

    RECRUITING

    Ahmedabad, India

  • Narayana Nethralaya

    RECRUITING

    Bangalore, India

  • Netralaya Super Speciality Eye Hospital

    RECRUITING

    Ahmedabad, India

  • PBMA'S H. V. Desai Eye Hospital

    RECRUITING

    Pune, India

  • Regional Institute of Ophthalmology (RIO) - Kolkata

    RECRUITING

    Kolkata, India

  • Regional Institute of Ophthalmology, Patna

    RECRUITING

    Patna, India

  • Shivam Retina Clinic and Eye Hospital

    RECRUITING

    Surat, India